tetrahydrocannabivarin

Small moleculeexperimental

Clinical trial activity

4 trials · 8 clinical orgs · 0 marketing orgs

Phase 1
1
Phase 2
3
Phase 3
0
Phase 4
0

Earliest trial started Oct 1, 2010 (NCT01217112)

Timeline

2010s

  1. Jan 1, 2010

    Earliest Phase 2 Sponsor(trial)

2020s

  1. Jan 1, 2022

    Earliest Phase 1 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

CCCc1cc(O)c2c(c1)OC(C)(C)[C@@H]1CCC(C)=C[C@@H]21
Mol. weight
286.42 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • gwp42004
  • tetrahydrocannabivarin

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT05574049Early Phase 1 (Phase 1)Jan 4, 2022Medical Life Care Planners, LLC
NCT02053272Phase 2Feb 1, 2014GW Research, University of Leicester
NCT01491490Phase 2Oct 1, 2011GW Research
NCT01217112Phase 2Oct 1, 2010GW Research, MAC UK Neuroscience Ltd, Mount Farm Surgery, Suffolk, University of East Anglia, University of Nottingham, Woolpit Health Centre
Showing 4 of 4 trials
Page 1 / 1

Organizations

Research & Development (8)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
GW ResearchFor profit3312010
MAC UK Neuroscience LtdFor profit1012010
Medical Life Care Planners, LLCAcademic/Hospital1112022
Mount Farm Surgery, SuffolkAcademic/Hospital1012010
University of East AngliaAcademic/Hospital1012010
University of LeicesterAcademic/Hospital1012014
University of NottinghamAcademic/Hospital1012010
Woolpit Health CentreAcademic/Hospital1012010
8 organizations
Page 1 / 1